Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Verona Pharma plc : 1st Quarter Results

Verona Pharma plc
Posted on: 08 Mar 18

LONDON, March 08, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on March 7, 2018, Dr. Jan-Anders Karlsson, Chief Executive Officer of the Company, purchased 3,250 ordinary shares of 5 pence each in the Company (the "Ordinary Shares") at a price of 148.64 pence per Ordinary Share.  Following the acquisition, Dr. Karlsson will have an interest in the Company of 92,400 Ordinary Shares, representing 0.09% of the Company's issued share capital.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

1 Details of the person discharging managerial responsibilities/person closely associated
a)Name Jan-Anders Karlsson

2 Reason for the notification




Chief Executive Officer

Initial notification/Amendment

Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameVerona Pharma plc
b) LEI


4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument

Identification code
Ordinary Shares of 5 pence each

b) Nature of the transaction

Jan-Anders Karlsson purchased 3,250 Ordinary Shares
c)Price(s) and volume(s)Price(s)Volume(s)
   148.64 pence per 
Ordinary Share
3,250 Ordinary 
d) Aggregated information

-  Aggregated volume
-  Price

e) Date of the transaction

7 March 2018
f) Place of the transaction

London Stock Exchange, AIM

For further information, please contact:

Verona Pharma plcTel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive
Stifel Nicolaus Europe Limited (Nominated Adviser
and UK Broker)
Tel: +44 (0) 20 7710 7600
Stewart Wallace / Jonathan Senior / Ben Maddison 

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Verona Pharma plc via GlobeNewswire

Last updated on: 09/03/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.